Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
Susan O'Brien, Jeffrey A. Jones, Steven E. Coutre, Anthony R. Mato, Peter Hillmen, Constantine Tam, Anders Österborg, Tanya Siddiqi, Michael J. Thirman, Richard R. Furman, Osman Ilhan, Michael J. Keating, Timothy G. Call, Jennifer R. Brown, Michelle Stevens-Brogan, Yunfeng Li, Fong Clow, Danelle F. James, Alvina D. Chu, Michael HallekStephan Stilgenbauer
Dive into the research topics of 'Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study'. Together they form a unique fingerprint.